Cardiology overview heart failure: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Pharmacotherapy== | ==Pharmacotherapy== | ||
===Angiotensin Converting Enzyme (ACE) Inhibition=== | |||
* Improve LV remodeling following ST elevation MI | |||
* Even in patients who are asymptomatic with LV dysfunction, this class improves the odds of developing symptoms and survival. | |||
===Lasix=== | ===Lasix=== | ||
*Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway. | *Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway. | ||
Revision as of 15:58, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pharmacotherapy
Angiotensin Converting Enzyme (ACE) Inhibition
- Improve LV remodeling following ST elevation MI
- Even in patients who are asymptomatic with LV dysfunction, this class improves the odds of developing symptoms and survival.
Lasix
- Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway.
Beta Blockers
Lopressor should be used instead of atenolol in the patient with CHF
Metformin
Enoxaparin and Antiocagulation
- While hospitalized, patients with CHF should receive DVT prophylaxis
Invasive Monitoring
- Based upon the results of the ESCAPE trial, there is no benefit in clinical outcomes with the use of a pulmonary artery line in patients with decompensated CHF.
Obstructive Sleep Apnea in the Patient with CHF
- Central sleep apnea in the patient with CHF is due to the compensatory respiratory alkalosis that is present in the patient with CHF and tachypnea